The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection.

Autor: Lampropoulou DI; Second Department of Medical Oncology, General Oncology Hospital of Kifissia 'Agioi Anargiroi', Athens, Nea Kifissia, Greece. d_lambropoulou@yahoo.gr., Bala VM; Second Department of Medical Oncology, General Oncology Hospital of Kifissia 'Agioi Anargiroi', Athens, Nea Kifissia, Greece., Zerva E; Second Department of Medical Oncology, General Oncology Hospital of Kifissia 'Agioi Anargiroi', Athens, Nea Kifissia, Greece., Pliakou E; Second Department of Medical Oncology, General Oncology Hospital of Kifissia 'Agioi Anargiroi', Athens, Nea Kifissia, Greece., Filippou D; Department of Anatomy and Surgical Anatomy, Medical School, National and Kapodistrian University of Athens, Athens, Greece., Gazouli M; Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens, Greece., Aravantinos G; Second Department of Medical Oncology, General Oncology Hospital of Kifissia 'Agioi Anargiroi', Athens, Nea Kifissia, Greece.
Jazyk: angličtina
Zdroj: Journal of infection in developing countries [J Infect Dev Ctries] 2022 Jan 31; Vol. 16 (1), pp. 101-111. Date of Electronic Publication: 2022 Jan 31.
DOI: 10.3855/jidc.15386
Abstrakt: Introduction: During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments.
Methodology: We reviewed recent literature (Pubmed, Google, Clinicaltrials.gov), as of the middle of May 2021, for evidence regarding the potential benefit from poly(ADP-ribose)-polymerase inhibitors and vascular endothelial growth factor blockade in severe SARS-CoV-2 infection.
Results: poly(ADP-ribose)-polymerase inhibitors have been suggested as potential agents against coronavirus disease 2019 (COVID-19) by a variety of mechanisms. vascular endothelial growth factor-associated vascular permeability is implicated with increased vascular leakage and pulmonary oedema. Thus, anti-angiogenesis factors, such as bevacizumab are being investigated in critically ill COVID-19 patients.
Conclusions: The synergistic potential of these two classes of inhibitors in severe COVID-19 management could be beneficial. Further research should be carried out in order to support this hypothesis.
Competing Interests: No Conflict of Interest is declared
(Copyright (c) 2022 Dimitra Ioanna Lampropoulou, Vanessa Meletia Bala, Eleni Zerva, Evangelia Pliakou, Dimitrios Filippou, Maria Gazouli, Gerasimos Aravantinos.)
Databáze: MEDLINE
Externí odkaz: